Cargando…
Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis
BACKGROUND: The beneficial outcome associated with the use of proton pump inhibitors (PPIs) in idiopathic pulmonary fibrosis (IPF) has been reported in retrospective studies. To date, no prospective study has been conducted to confirm these outcomes. In addition, the potential mechanism by which PPI...
Autores principales: | Ghebremariam, Yohannes T, Cooke, John P, Gerhart, William, Griego, Carol, Brower, Jeremy B, Doyle-Eisele, Melanie, Moeller, Benjamin C, Zhou, Qingtao, Ho, Lawrence, de Andrade, Joao, Raghu, Ganesh, Peterson, Leif, Rivera, Andreana, Rosen, Glenn D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522053/ https://www.ncbi.nlm.nih.gov/pubmed/26231702 http://dx.doi.org/10.1186/s12967-015-0614-x |
Ejemplares similares
-
Proton-Pump Inhibitor Utilization Associated With the Change to Nonpreferred Formulary Status for Esomeprazole in the TRICARE Formulary
por: Linton, Andrea, et al.
Publicado: (2009) -
Evaluation of Proton Pump Inhibitor Esomeprazole on Crizotinib Pharmacokinetics in Healthy Participants
por: Xu, Huiping, et al.
Publicado: (2021) -
Combination of esomeprazole and pirfenidone enhances antifibrotic efficacy in vitro and in a mouse model of TGFβ-induced lung fibrosis
por: Ebrahimpour, Afshin, et al.
Publicado: (2022) -
Esomeprazole attenuates inflammatory and fibrotic response in lung cells through the MAPK/Nrf2/HO1 pathway
por: Ebrahimpour, Afshin, et al.
Publicado: (2021) -
Evaluation of the pharmacokinetics of trazpiroben (TAK‐906) in the presence and absence of the proton pump inhibitor esomeprazole
por: Kaur Mukker, Jatinder, et al.
Publicado: (2022)